Business Context and Reporting Period
This Form 8-K was filed by AntriaBio, Inc. (not Rezolute, Inc.) on May 9, 2017, reporting events occurring on May 4, 2017. The filing details the second closing of a planned private placement transaction (PIPE Financing) with investors in the Republic of Korea.
Key Financial Metrics
- Transaction Type: Private placement of Common Stock.
- Shares Issued: 2,226,190 shares.
- Price Per Share: $1.00.
- Gross Proceeds: $2.2 million (excluding transaction costs, fees, and expenses).
- Total Financing Goal: The Company is seeking to raise at least $15.0 million through this ongoing PIPE Financing.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash flow, or overall liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the issuance of 2,226,190 shares. This represents a partial fulfillment of the Company's capital raise strategy, with subsequent closings planned to reach the $15.0 million target.
Guidance, Outlook, and Risks
- Outlook: The Company plans to conduct subsequent closings to complete the PIPE Financing, though no assurance is given that the $15.0 million target will be achieved.
- Registration Rights: The Company agreed to file a registration statement within 30 days of the final close to allow investors to resell shares under Rule 144.
- Risks and Contingencies: The securities were sold under Section 4(a)(2) and Rule 506 exemptions and are not registered. They may not be offered or sold in the United States absent registration or an applicable exemption.
- Unusual Items: None reported beyond the standard terms of the private placement.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the timeline and status of the remaining closings required to reach the $15.0 million goal.
- Review the filed Registration Statement once available to confirm the effectiveness of resale rights for investors.
- Check subsequent filings for updates on the utilization of the $2.2 million gross proceeds.